Adjuvant Therapy for Gastric Carcinoma Patients in the Past 15 Years

Ken Shimada and Jaffer A. Ajani
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 1 de noviembre del 2001

Share article


Imprima English

Reviewers: Li Liu, MD
Source: Cancer, 86(9):1657-1668, November 1999.


Précis: The routine use of adjuvant therapy for patients with gastric carcinoma apperrs difficult to justify.

Introduction

In 1998, gastric cancer was the 9th leading cause of cancer related death in the United States and the second leading cause in the world. The symptoms and/or signs of gastric cancer are generally nonspecific and the majority of patients present with advanced disease. Routine screening for gastric cancer is generally not performed in western countries because of the low prevalence of the disease. When the tumor is respectable, curative surgery is the mainstay of treatment. Adjuvant therapies have been investigated extensively for more than 30 years. This report by Drs. Shimada and Ajani is a comprehensive review of the role of adjuvant therapy for this disease.

Method

All randomized studies since 1984 were reviewed.

Results

  • There were some marked differences in the strategies employed between the West and Asia.

  • Postoperative adjuvant therapy did not appear to be beneficial in Western studies.

  • The results of the Asian trials demonstrated a benefit to adjuvant therapy; however, only in subgroup analyses of patients with relatively early stage disease was this benefit observed.

  • Despite lack of definitive evidence for efficacy, most Asian patients receive postoperative or perioperative adjuvant chemoimmunothearpy.

Discussion

The routine use of adjuvant therapy for patients with gastric carcinoma is difficult to justify. Further investigation using novel anticancer agents with unique mechanisms of action, such as angiogenesis inhibitors, metalloproteinase inhibitors, antibodies to oncogenes, or gene therapy, are warranted.

Imprima English
News
Adjuvant S-1 Improves Five-Year Outcomes in Gastric Cancer

Oct 20, 2011 - Postoperative adjuvant therapy with oral fluoropyrimidine derivative, S-1, improves overall and relapse-free survival at five years in patients with stage II or III gastric cancer who undergo D2 gastrectomy, according to a study published online Oct. 17 in the Journal of Clinical Oncology.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información